• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Dss, Inc. claimed ownership of 1,678,682 shares (SEC Form 3)

    9/17/24 6:16:26 AM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBO alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    DSS, INC.

    (Last) (First) (Middle)
    1400 BROADFIELD BLVD., SUITE 130

    (Street)
    HOUSTON TX 77084

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/16/2024
    3. Issuer Name and Ticker or Trading Symbol
    IMPACT BIOMEDICAL INC. [ IBO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 1,678,682 I See Footnote(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. DSS indirectly owns 1,345,482shares through DSS BioHealth Security, Inc., its wholly-owned subsidiary, 166,600 shares through DSS Securities, Inc. and 166,600 shares through DSS BlockChain Security, Inc.
    /s/ Frank D. Heuszel 09/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IBO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IBO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IBO
    SEC Filings

    See more
    • SEC Form PRE 14C filed by Impact BioMedical Inc.

      PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

      7/16/25 4:30:05 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impact BioMedical Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

      6/23/25 7:45:39 AM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Impact BioMedical Inc.

      10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

      5/14/25 4:15:42 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Dss, Inc. sold $249,408 worth of shares (53,300 units at $4.68) and bought $310 worth of shares (200 units at $1.55) (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      3/24/25 8:00:38 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      12/9/24 4:05:17 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      12/3/24 9:51:36 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

      A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact B

      6/23/25 7:52:44 AM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impact Biomedical Inc. Announcement Stock Activity/Pricing

      HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE:IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through re

      3/21/25 2:38:33 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

      ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE:IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS' ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purification technology featuring a patented three-stage filtration system capable of removing ultrafine particles as small as ten (10) nanometers, helping to improve indoor air quality and mitigate airborne health risks. The sale

      2/26/25 8:30:00 AM ET
      $DSS
      $IBO
      Containers/Packaging
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Dss, Inc. sold $845,013 worth of shares (890,800 units at $0.95), decreasing direct ownership by 85% to 161,100 units (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      4/7/25 9:59:28 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chan Heng Fai Ambrose sold $174,020 worth of shares (351,555 units at $0.49) (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      4/7/25 5:18:49 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chan Heng Fai Ambrose sold $1,122,920 worth of shares (1,689,693 units at $0.66) (SEC Form 4)

      4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

      4/4/25 5:15:33 PM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

      A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact B

      6/23/25 7:52:44 AM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBO
    Financials

    Live finance-specific insights

    See more
    • Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"

      HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedical's focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness. Celios® brings advanced air purification capability, featuring design, system, and method patents

      2/26/25 8:30:00 AM ET
      $IBO
      Biotechnology: Pharmaceutical Preparations
      Health Care